戈利木单抗用于治疗强直性脊柱炎时可能诱发炎症性肠病加重：一例病例报告并文献复习
Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: a case report with a review of literature.
作者信息
Bawany Muhammad Z, Rafiq Ehsan, Thotakura Raja, Lay Roberta, Silverman Ann L, Nawras Ali
机构信息
1Internal Medicine Department, University of Toledo Medical Center, Toledo, OH 2Division of Gastroenterology, UP Digestive Health, War Memorial Hospital, Marie, MI.
出版信息
Am J Ther. 2014 Jan-Feb;21(1):e26-7. doi: 10.1097/MJT.0b013e31825e6089.
Golimumab is a human IgG monoclonal antibody specific for human tumor necrosis factor alpha. Golimumab has been approved for use in rheumatological conditions; however, its use in inflammatory bowel disease is still being evaluated in clinical trials. We report a case of an exacerbation of ulcerative proctitis after starting on golimumab for ankylosing spondylitis.
戈利木单抗是一种针对人肿瘤坏死因子α的人IgG单克隆抗体。戈利木单抗已被批准用于治疗风湿性疾病；然而，其在炎症性肠病中的应用仍在临床试验中进行评估。我们报告了一例在开始使用戈利木单抗治疗强直性脊柱炎后，溃疡性直肠炎病情加重的病例。
Zotero 插件